Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

New developments in the treatment of pancreatic cancer

A booster dose of a substance already found in the body appears to be safe and non-toxic for the treatment of pancreatic cancer, and shows signs of arresting pancreatic cancer cell growth in patients, Penn State College of Medicine researchers report.

20 Apr 2004

LAM Pharmaceutical receives approval to sell it's wound gel in China

LAM Pharmaceutical, a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that the Chinese State Food and Drug Administration ("SFDA") has granted approval for the importation and sale of its patented LAM IPM Wound Gel(TM) in China

24 Mar 2004

Carbon Dioxide may be used in medical implants

Carbon dioxide, an environmentally friendly solvent for dyeing and dry cleaning, may become a valuable new tool for making medical implants, according to a study at Ohio State University.

23 Mar 2004

Tiny Ribozyme package could be future treatment of Hepatitis B virus

Penn State College of Medicine researchers have developed a tiny package that searches for and destroys up to 80 percent of hepatitis B virus in the livers of mice.

22 Mar 2004

New drug to treat urinary tract infections, a step closer

Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections. The data confirmed Phase II results, demonstrating that Depomed's once-daily Ciprofloxacin GR eliminated the organisms responsible for urinary tract infections as effectively as twice-daily CIPRO(R), but with fewer gastrointestinal side effects, specifically fewer incidences of nausea and diarrhea.

22 Mar 2004

Atrix Signs Feasibility Agreement for Development of Two New Compounds

Atrix Laboratories, Inc. has announced today that the company has signed a limited feasibility agreement with Aventis SA (NYSE: AVE) to begin preliminary research on two proprietary Aventis compounds formulated in Atrix's delivery technology, Atrigel®. The current agreement is specific for these compounds in an undisclosed therapeutic area.

22 Mar 2004